Cystic fibrosis is a genetic disease that causes ... However, it does not always eradicate the bacteria responsible for respiratory infections. By studying 3D models of human lung cells ...
NA: Not available. Cystic fibrosis (CF) pulmonary disease is characterized by chronic and recurrent infection, and airway inflammation. Colonization and chronic airway infection with bacterial ...
BX-004 is under development for the treatment of cystic fibrosis, non-cystic fibrosis bronchiectasis and resistant pseudomonas aeruginosa infections. It is administered as inhalational formulation.
Cystic fibrosis is a genetic disorder driven by CFTR mutations that affects the exocrine glands. Manifesting with excessively viscous mucus production, patients typically experience obstruction of ...
The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...
LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved a once-daily oral combination of ...
Cystic fibrosis is a genetic disorder that primarily affects the lungs and pancreas, causing persistent respiratory infections, severe digestive issues, and other complications. Symptoms include ...